You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

Article metrics

Article menu
Oncology
Original research
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

 

Online download statistics by month:

Online download statistics by month: September 2022 to April 2024

AbstractFullPdf
Sep 202210531055153
Oct 202246346274
Nov 202233333243
Dec 202234033724
Jan 202331030830
Feb 202320820631
Mar 2023373920
Apr 2023353417
May 2023434430
Jun 2023464627
Jul 2023424213
Aug 2023414121
Sep 2023403714
Oct 2023434126
Nov 2023623730
Dec 2023655738
Jan 2024684723
Feb 2024575430
Mar 2024605456
Apr 2024393828
Total33853311728